Can-Fite BioPharma Ltd.
Business
Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company developing orally bioavailable small-molecule therapeutic products targeting the A3 adenosine receptor for cancer, liver and inflammatory diseases. Its pipeline includes Piclidenoson (psoriasis, Lowe Syndrome), Namodenoson (hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis, pancreatic cancer) and CF602 (erectile dysfunction), all in clinical or preclinical development. The company generates revenues through out-licensing agreements with pharmaceutical partners in Canada, South Korea, China, Central Europe and the veterinary sector.
Summary from 20-F filed 2026-03-26
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $405.0K |
| Net income | $-9.83M |
| Total assets | $9.51M |
| Total liabilities | — |
| Stockholders' equity | $5.59M |
| Operating cash flow | $-8.95M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Can-Fite BioPharma Ltd.'s CIK number?
Can-Fite BioPharma Ltd.'s SEC CIK number is 0001536196 (1536196). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Can-Fite BioPharma Ltd.'s SEC filings?
All of Can-Fite BioPharma Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.